Form 4: Milestone Pharmaceuticals CEO Joseph Oliveto Boosts Stake with Unit Acquisition

Milestone Pharmaceuticals Inc.'s President and CEO, Joseph Oliveto, has increased his direct beneficial ownership by acquiring 66,666 common shares and associated warrants through a unit purchase.

Summary

• Joseph Oliveto, who serves as President and CEO and a Director of Milestone Pharmaceuticals Inc. (MIST), acquired additional securities.
• The transaction took place on July 11, 2025.
• Mr. Oliveto purchased 66,666 Issuer Units at a price of $1.50 per Unit.
• Each Issuer Unit consists of one common share, one Series A common warrant, and one Series B common warrant.
• Each Series A common warrant provides the right to purchase one common share at an exercise price of $1.50 and expires on July 11, 2026.
• Each Series B common warrant provides the right to purchase one common share at an exercise price of $1.875 and expires on July 11, 2030.
• Following this transaction, Mr. Oliveto's direct beneficial ownership of common shares stands at 347,221.
• He also directly beneficially owns 66,666 Series A common warrants and 66,666 Series B common warrants.

Sentiment

Score: 7

Explanation: The acquisition of additional shares and warrants by the President and CEO indicates confidence in the company's future prospects and is generally viewed as a positive signal by the market.

Positives

• President and CEO Joseph Oliveto significantly increased his direct beneficial ownership in Milestone Pharmaceuticals Inc. by acquiring 66,666 common shares and 133,332 warrants (66,666 Series A and 66,666 Series B).
• The acquisition of units at $1.50 per unit, which includes common shares and warrants, demonstrates management's direct financial investment and confidence in the company's future prospects and valuation.

Future Outlook

NA

Industry Context

This filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The acquisition by a key executive may instill greater confidence among existing and potential shareholders, signaling strong internal belief in the company's value and future performance.

Key Dates

Recommendation

Keywords

Milestone Pharmaceuticals, MIST, Joseph Oliveto, Insider Trading, Stock Acquisition, Warrants, CEO, SEC Form 4, Beneficial Ownership